Table 4.
The association between pre-operative expression of exosomal peptides and MACIS (metastasis, age, completeness of resection, invasion, and size).
| Variable | MACIS | p-Value | |
|---|---|---|---|
| <7 (n = 16) | ≥7 (n = 5) | ||
| Pre-op exosome expression | |||
| UEx Thyroglobulin | 1.35 (0.62–3.91) | 1.87 (1.18–1.88) | 0.73 b |
| UEx Galectin-3 | 0.76 (0.59–1.55) | 1.90 (1.60–2.84) | 0.12 b |
| UEx Transketolase | 0.52 (0.27–2.17) | 1.62 (0.95–23.84) | 0.30 b |
| UEx Calprotectin A8 | 24.10 (1.42–61.80) | 37.81 (17.56–62.35) | 0.30 b |
| UEx Calprotectin A9(2) * | 26.31 (5.96–70.39) | 31.77 (30.03–241.96) | 0.39 b |
| UEx Calprotectin A9(13) * | 5.55 (5.14–62.39) | 17.07 (9.46–22.29) | 0.54 b |
| UEx Annexin-2 | 43.81 (20.47–194.20) | 45.60 (28.48–58.62) | 0.84 b |
| UEx Afamin | 0.60 (0.00–0.81) | 0.00 (0.00–0.49) | 0.35 b |
| UEx Angiopoietin-1 | 0.57 (0.00–1.38) | 0.56 (0.00–1.32) | 1.00 b |
| UEx Keratin-19 | 0.79 (0.53–1.39) | 0.69 (0.57–1.67) | 1.00 b |
| UEx TIMP (5) * | 1.31 (0.94–1.95) | 1.93 (0.00–3.49) | 0.84 b |
| UEx TIMP (14) * | 0.68 (0.21–1.20) | 4.48 (1.48–8.28) | 0.12 b |
| UEx Keratin 8 (8) * | 0.45 (0.34–0.67) | 0.23 (0.11–1.60) | 0.74 b |
| UEx Keratin 8 (17) * | 0.99 ± 0.64 | 1.40 ± 1.09 | 0.31 a |
| Demography | |||
| Gender | 1.00 c | ||
| Male | 14 (77.78%) | 4 (22.22%) | |
| Female | 2 (66.67%) | 1 (33.33%) | |
| Age | 47.94 ± 7.38 | 62 ± 11.68 | 0.004 a |
| Hypertension | 0.23 c | ||
| Yes | 2 (50.00%) | 2 (50.00%) | |
| No | 14 (82.35%) | 3 (17.65%) | |
| Diabetes (type 2) | 0.004 c | ||
| Yes | 1 (20.00%) | 4 (80.00%) | |
| No | 15 (93.75%) | 1 (6.25%) | |
| Clinical parameters | |||
| TNM stage | 0.008 c | ||
| I | 16 (88.89) | 2 (11.11) | |
| II | 0 (0.00) | 3 (100.00) | |
| Tumor size | 1.45 (0.85–1.65) | 1.1 (1.0–1.5) | 0.90 b |
| Tumor multifocality | 0.048 c | ||
| Yes | 0 (0.00%) | 2 (100.00%) | |
| No | 16 (84.21%) | 3 (15.79%) | |
| Extrathyroid invasion | 5 (83.33%) | 1 (16.67) | 0.85 c |
| I-131 treatment | 0.21 c | ||
| No | 5 (83.33%) | 1 (16.67%) | |
| 1 time | 10 (83.33%) | 2 (16.67%) | |
| 2 times | 1 (33.33%) | 2 (66.67%) | |
| I-131 cumulative dose | 30.6 (0–130 mCi) | 84 (30–300 mCi) | 0.32 b |
| ATA (IU/mL) | 0.45 c | ||
| <3 | 9 (81.82%) | 2 (18.18%) | |
| ≥3 | 7 (70.00%) | 3 (30.00%) | |
| TPO Ab (IU/mL) | 0.45 c | ||
| <3 | 12 (80.00%) | 3 (20.00%) | |
| ≥3 | 4 (66.67%) | 2 (33.33%) | |
| Post-operative TSH (IU/mL) | 4.55 (0.98–78.85) | 71.28 (23.30–111.00) | 0.49 b |
ATA: anti-thyroglobulin antibody; TPO Ab: thyroid peroxidase antibody; Note: There was 1 patient missing of UExTg and UEx Galectin-3. Bold value denotes statistically significant, p < 0.05. a Using Student’s t-test. b Using Wilcoxon rank sum test. c Using Fisher’s exact test. * The numbers in brackets are peptide No. (Table 3).